Related Experiment Video
Updated: Nov 27, 2025
11:11
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
7.7K
Targeting Casein Kinase 1 (CK1) in Hematological Cancers
Pavlína Janovská1, Emmanuel Normant2, Hari Miskin2
1Department of Experimental Biology, Faculty of Science, Masaryk University, 62500 Brno, Czech Republic.
International Journal of Molecular Sciences
|December 2, 2020
Summary
Casein kinase 1 (CK1) inhibitors show promise in treating blood cancers like CLL and AML by targeting key pathways. Further research is ongoing for CK1 isoform-specific therapies in hematological malignancies.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Casein kinase 1 (CK1) enzymes are serine/threonine kinases crucial for cellular processes.
- CK1 isoforms regulate pathways implicated in hematological malignancies, including Wnt signaling, proliferation, apoptosis, and autophagy.
Purpose of the Study:
- To review recent advancements in understanding CK1 biology.
- To explore the therapeutic potential of CK1 inhibition in various blood cancers.
Main Methods:
- Literature review of preclinical and clinical studies on CK1 inhibitors.
- Analysis of CK1 isoform roles in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphomas (NHL), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and multiple myeloma (MM).
Main Results:
- CK1δ/ε inhibitors demonstrated efficacy in preclinical CLL models by targeting the WNT-5A/ROR1 pathway.
- CK1α inhibition showed preclinical promise in MDS, AML, and MM via p53 pathway activation.
- Umbralisib, a dual PI3Kδ and CK1ε inhibitor, is in clinical trials for CLL and NHL.
Conclusions:
- CK1 isoforms represent viable therapeutic targets for hematological malignancies.
- Targeted inhibition of specific CK1 isoforms holds potential for novel cancer treatments.
- Clinical trials are underway for CK1-targeting agents, indicating promising therapeutic avenues.
Related Concept Videos
02:57Targeted Cancer Therapies
8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.2K
03:03mTOR Signaling and Cancer Progression
4.2K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.2K
02:34Inhibition of Cdk Activity
5.4K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
02:15M-Cdk Drives Transition Into Mitosis
6.0K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.5K
01:22PI3K/mTOR/AKT Signaling Pathway
4.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.8K